Cargando…
Schlafen 5 as a Novel Therapeutic Target in Pancreatic Ductal Adenocarcinoma
We provide evidence that a member of the human Schlafen (SLFN) family of proteins, SLFN5, is overexpressed in human pancreatic ductal adenocarcinoma (PDAC). Targeted deletion of SLFN5 results in decreased PDAC cell proliferation and suppresses PDAC tumorigenesis in in vivo PDAC models. Importantly,...
Autores principales: | Fischietti, Mariafausta, Eckerdt, Frank, Blyth, Gavin T., Arslan, Ahmet D., Mati, William M., Oku, Chidera V., Perez, Ricardo E., Lee-Chang, Catalina, Kosciuczuk, Ewa M., Saleiro, Diana, Beauchamp, Elspeth M., Lesniak, Maciej S., Verzella, Daniela, Sun, Leyu, Fish, Eleanor N., Yang, Guang-Yu, Qiang, Wenan, Platanias, Leonidas C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106654/ https://www.ncbi.nlm.nih.gov/pubmed/33846574 http://dx.doi.org/10.1038/s41388-021-01761-1 |
Ejemplares similares
-
Human SLFN5 is a Transcriptional Co-repressor of STAT1-Mediated Interferon Responses and Promotes the Malignant Phenotype in Glioblastoma
por: Arslan, Ahmet Dirim, et al.
Publicado: (2017) -
Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms
por: Saleiro, Diana, et al.
Publicado: (2022) -
Inhibitory effects of SEL201 in acute myeloid leukemia
por: Kosciuczuk, Ewa M., et al.
Publicado: (2019) -
Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells
por: Saleiro, Diana, et al.
Publicado: (2023) -
PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)